CSL Limited (CSLLY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Melbourne, VIC, Australia. Der aktuelle CEO ist Gordon Naylor DipCompSc.
CSLLY hat IPO-Datum 2009-12-29, 32,698 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $95.92B.
CSL Limited is a global biopharmaceutical company headquartered in Parkville, Australia, with operations across the United States, Europe, China, and other international markets. The company operates through two primary divisions: CSL Behring, which specializes in plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, and neurological conditions, and Seqirus, which focuses on non-plasma biotherapeutics and influenza-related products. CSL Limited researches, develops, manufactures, and distributes a comprehensive portfolio of biopharmaceutical products while also generating revenue through licensing and royalty agreements. Founded in 1916, the company has established itself as a leader in the biopharmaceutical industry through its innovative therapeutic solutions and global market presence.
